TherapeuticsMD, Inc.
TXMDNASDAQHealthcareDrug Manufacturers - Specialty & Generic
Previous close
$2.06
$0.00 · 0.00%
TXMD company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
72
Undervalued
Momentum
43
Neutral
Sentiment
54
Mixed
Risk resilience
38
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteTherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Marlan D. Walker
- Listed since
- May 9, 2007
- Employees
- 1
Market position
Day range
Current $2.06
52-week range
Current $2.06
- Open
- $2.06
- Previous close
- $2.06
- Volume
- 3.43K
- 0.1× average
- Average volume
- 32.83K
- Average daily volume
- Market cap
- 23.84M USD
- Beta
- 0.64
- Market reference 1
- 50-day average
- $2.0594
- +0.03% above average
- 200-day average
- $2.0295
- +1.51% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 17.47M USD
- P/E (TTM)
- -114.44×
- P/B (TTM)
- 0×
- P/S (TTM)
- 7.29×
- EV / EBITDA
- -5.78×
- Earnings yield
- -3.02%
- Free cash flow yield
- 12.85%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 89.94%
- Operating margin
- -117.80%
- Net margin
- -6.64%
- Return on equity
- -2.12%
- Return on assets
- -1.51%
- Return on invested capital
- -12.45%
Financial health
- Debt / equity
- 0.2×
- Current ratio
- 3.02×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.02M USD | 1.76M USD | 1.3M USD | 69.96M USD | 2.57M USD |
| Cost of goods sold | — | — | — | 1.4M USD | 1.4M USD |
| Gross profit | 3.02M USD | 1.76M USD | 1.3M USD | 68.57M USD | 1.17M USD |
| Selling, general, and administrative | 6.85M USD | 6.1M USD | 8.9M USD | 56.71M USD | 80.75M USD |
| Operating expenses | 7.24M USD | 6.61M USD | 9.83M USD | 57.9M USD | 80.75M USD |
| Interest income | 150K USD | — | 300K USD | — | — |
| Interest expense | 8K USD | — | 200K USD | — | 32.92M USD |
| Depreciation and amortization | 1.19M USD | 1.28M USD | 922K USD | 1.2M USD | 736K USD |
| Operating income | −4.21M USD | −4.84M USD | −8.52M USD | 10.66M USD | −79.58M USD |
| Net income | −569K USD | −2.18M USD | −10.28M USD | 112M USD | −172.42M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 38%
- 3 beats, 5 misses, 0 met estimates
- Average EPS surprise
- -124.83%
- 8 comparable reports
- Latest EPS result
- 0.01
- Estimate -6.13 · Beat by 100.16%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 9, 2022 | 1:50 | — | — |
Stock split | Oct 3, 2011 | 1:100 | — | — |
Stock split | Jul 27, 2009 | 3:1 | — | — |
Effective May 9, 2022
1:50
Effective Oct 3, 2011
1:100
Effective Jul 27, 2009
3:1
TXMD peers
ETFs holding TXMD
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI495.96K0.00%2.3T USD0.03%$378.24+0.44%
Vanguard Extended Market ETFVXF222.04K0.00%93.7B USD0.05%$245.53+0.82%
Dimensional - US Core Equity 2 ETFDFAC9.94K0.00%49.31B USD0.17%$45.61+0.46%
Dimensional - US Sustainability Core 1 ETFDFSU7.44K0.00%2.35B USD0.15%$48.20+0.52%
Dimensional - US Core Equity 1 ETFDCOR6.34K0.00%3.51B USD0.14%$84.54+0.42%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 495.96K
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 222.04K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
Dimensional - US Core Equity 2 ETFDFAC- Market value
- 9.94K
- Weight
- 0.00%
- AUM
- 49.31B USD
- Expense ratio
- 0.17%
- Price / 1D
- $45.61+0.46%
Dimensional - US Sustainability Core 1 ETFDFSU- Market value
- 7.44K
- Weight
- 0.00%
- AUM
- 2.35B USD
- Expense ratio
- 0.15%
- Price / 1D
- $48.20+0.52%
Dimensional - US Core Equity 1 ETFDCOR- Market value
- 6.34K
- Weight
- 0.00%
- AUM
- 3.51B USD
- Expense ratio
- 0.14%
- Price / 1D
- $84.54+0.42%
Continue in GoAI
Research TXMDresearch.disclaimer